1. Search Result
Search Result
Results for "

Apoe Inhibitors

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

2

Peptides

5

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0119
    Lixisenatide
    2 Publications Verification

    GCGR MEK Akt MMP JNK Neurological Disease Metabolic Disease Inflammation/Immunology
    Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe −/− Irs 2+/− mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .
    Lixisenatide
  • HY-112540B
    Acetoacetic acid sodium
    3 Publications Verification

    Endogenous Metabolite Metabolic Disease
    Acetoacetic acid sodium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid sodium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid sodium can be used to study metabolic diseases .
    Acetoacetic acid sodium
  • HY-112540A
    Acetoacetic acid lithium
    3 Publications Verification

    Endogenous Metabolite Metabolic Disease
    Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .
    Acetoacetic acid lithium
  • HY-N0704
    Agrimol B
    1 Publications Verification

    Sirtuin PPAR Fatty Acid Synthase (FASN) c-Myc Bacterial Infection Metabolic Disease Cancer
    Agrimol B, a polyphenol, is an orally active and potent SIRT1 activator. Agrimol B shows anti-adipogenic and anticancer activity. Agrimol B shows antibacterial activity against plant pathogens. Agrimol B dramatically inhibits 3T3-L1 adipocyte differentiation by reducing PPARγ, C/EBPα, FAS, UCP-1, and apoE expression. The action of Agrimol B on the cancer cells is likely derived from its effect on c-MYC, SKP2 and p27 .
    Agrimol B
  • HY-176434

    Sirtuin Neurological Disease
    DDL-218 is an orally active and potent SirT1 inhibitor. DDL-218 enhances SirT1 in ApoE4-expressing neurons and a murine AD model. DDL-218 can be used in the study of Alzheimer's disease .
    DDL-218
  • HY-173591

    Formyl Peptide Receptor (FPR) Apoptosis Reactive Oxygen Species (ROS) Interleukin Related Cardiovascular Disease
    T0080 is a FPR-1 antagonist. T0080 reduces the cell apoptosis, inhibits ROS production and pro-inflammatory cytokines (TNF-α and IL-1β) from plaque macrophages, which attenuates atherosclerotic progression in ApoE −/− mice .
    T0080
  • HY-W424839

    DTBP

    Heme Oxygenase (HO) Cardiovascular Disease
    Probucol dithiobisphenol (DTBP) is the derivative of Probucol (HY-B0388). Probucol dithiobisphenol induces the production of heme oxygenase 1 (HO-1), and exhibits antioxidant activity. Probucol dithiobisphenol inhibits atherosclerotic lesions in Apoe −/− mice aorta, promotes re-endothelialization of aorta and inhibits restenosis in rabbit arterial injury models. Probucol dithiobisphenol is orally active .
    Probucol dithiobisphenol
  • HY-173234

    Pyroptosis Cardiovascular Disease
    GI-Y2 is an inhibitor of GSDMD and can inhibit Pyroptosis of macrophages induced by oxidized low-density lipoprotein (ox-LDL). In vivo, GI-Y2 can dose-dependently reduce atherosclerotic plaques in ApoE-/- mice and decrease the lesion size and fibrosis degree of the aortic root. GI-Y2 is expected to be used in the research of pyroptosis and cardiovascular diseases, such as atherosclerosis .
    GI-Y2
  • HY-P0119S

    Isotope-Labeled Compounds GCGR MEK Akt MMP JNK Neurological Disease
    Lixisenatide (Leu- 13C6, 15N) TFA is the 13C- and 15N-labeled Lixisenatide (HY-P0119). Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe ?/? Irs 2+/? mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .
    Lixisenatide (Leu-13C6,15N) TFA
  • HY-112540

    Endogenous Metabolite Metabolic Disease
    Acetoacetic acid is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid can be used to study metabolic diseases .
    Acetoacetic acid
  • HY-112540AR

    Endogenous Metabolite Metabolic Disease
    Acetoacetic acid (lithium) (Standard) is the analytical standard of Acetoacetic acid (lithium). This product is intended for research and analytical applications. Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .
    Acetoacetic acid lithium (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: